The plastic packaging and container manufacturing company Industrias Plásticas Triana, a member of Catalonia.health, has obtained ISCC Plus and UNE-EN 15343certifications, two important milestones in its sustainability strategy. 

Personalised medicine company Inbiomotion, a member of Catalonia.health, announces that MAF Test® will be available at the Hospital del Mar in Barcelona, also a member of Catalonia.health, the Clínic Barcelona Comprehensive Cancer Center, the HM Hospitals centres in the Community of Madrid, and the International Breast Cancer Center/Pangaea Oncology (Barcelona).

The biotechnology company Microomics, a member of Catalonia.health, has announced a restructure of its executive team in order to embark on a new growth phase.

The biopharmaceutical company Oryzon Genomics, a member of Catalonia.health, has announced that they have received the “Decision to grant” communications from the Canadian Intellectual Property Office and the Israel Patent Office for its patent applications CA3071804and IL272092

The deeptech company DevsHealth, a member of Catalonia.health, and the Foundation for the Research of Neglected Diseases (FNDR), based in India, announce the identification of DHFLV_003B, the first antiviral compound against dengue conceived entirely with AI thanks to the DevsHealth computational platform.

The financial services company Inveready, a member of Catalonia.health, announces the successful closure of its life sciences fund Inveready Innvierte Biotech II.

The pharmaceutical company Medichem, a member of Catalonia.health, have earned B Corp certification, awarded by B Lab. With this recognition, Medichem joins a global movement of companies that meet high standards of social and environmental performance, transparency, and corporate accountability.

Biotechnology company Admit Therapeutics, a member of Catalonia.health, announced its relocation to new, expanded laboratory and office spaces within Almirall’s Innovation Hub "The Hive" at the existing R&D center in Sant Feliu de Llobregat, also a member of Catalonia.health.

The startup The Smart Lollipop, a member of Catalonia.health, has opened an investment round Series A of 2.5 million euros in order to launch its smart candy that diagnoses diseases with saliva analysis.

Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company and a European leader in epigenetics announced that it has submitted the clinical trial  protocol for its Phase III PORTICO-2 trial to the U.S. FDA to initiate a registrational trial to evaluate vafidemstat in patients with Borderline Personality Disorder (BPD).

The engineering company Biorem, a member of CATALONIA.HEALTH, has developed a virtual reality platform that allows to visualize bioprinting solutions of organs and tissues on the human body. 

The biotechnology company Gate2Brain, a member of CATALONIA.HEALTH, has announced that its lead candidate, G2B-002, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA).

The financial services company Inveready, a member of CATALONIA.HEALTH, has successfully completed the fundraising of its second private equity fund, Inveready Innvierte Private Equity II, and formalizes the first two investments of the same fund with the acquisition of a share in Avatel Telecom and the investment in Tekman Education.

The spin-off company from Vall d’Hebron Institute of Research (VHIR) D-Sight, both members of CATALONIA.HEALTH, has been awarded with the Disruptive Innovation Award at the 18th edition of the EmprendeXXI Awards. 

The biopharmaceutical company AbilityPharma, a member of CATALONIA.HEALTH, announced that the data of its Phase I/IIa ENDOLUNG trial evaluating Ibrilatazar (ABTL0812) in combination with chemotherapy (paclitaxel/carboplatin) for patients with stage III/IV squamous non-small cell lung cancer (sq-NSCLC) has been published in the Lung Cancer journal.

The project aims to improve children's medical care at home by analysing indoor pollutants and producing personalised digital recommendations for families and health professionals. AYRA is coordinated by a consortium of the same name made up of the Hospital Sant Joan de Déu Barcelona, CATALONIA.HEALTH, the BCD Foundation, Domestic Data Streamers, PUMBA and TheLeftBit, leading organisations in health, design, technology and data visualisation.

The clinical-stage biotechnology company OneChain Immunotherapeutics, a member of CATALONIA.HEALTH, has announced the appointment of Barbara Krebs-Pohl as the new Chair of the Board of Directors. 

Aortyx, the Barcelona-based medtech scaleup and CATALONIA.HEALTH members, has raised 13.8M EUR Series A funding round led by Ship2B Ventures. The funding will be used to reach the milestone of first-in-human readiness, bringing their product – a bioresorbable patch that treats aortic tears – closer to market.

SpliceBio has announced the closing of a $135 million Series B financing round. The round, the largest in the biotech sector in Spain, is co-led by new investors EQT Life Sciences and Sanofi Ventures, with the participation of Roche Venture Fund, and all existing investors.

Despite a global context in which investment has decreased in 2024, the data from Catalonia reflect a positive trend, as anticipated in last year's study, which predicted a global increase that would be transferred to the local market months later. For its part, according to the Bioregió study, medtech with 131 million euros is the subsector with the most significant increase in 2024, almost tripling the level of 2023. In the same line of growth is biotechnology, with 29 million euros.